Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line treatment for patients with unresectable hepatocellullar carcinoma (HCC).
Epistemonikos ID: 98263c14c5eb7d2bb7e549ca1e36c859e3e0c8bd
First added on: Dec 20, 2022